JP2021522295A - プリオンおよびプリオン様疾患の治療のためのｓｅｒｐｉｎ阻害剤 - Google Patents

プリオンおよびプリオン様疾患の治療のためのｓｅｒｐｉｎ阻害剤 Download PDF

Info

Publication number
JP2021522295A
JP2021522295A JP2020561004A JP2020561004A JP2021522295A JP 2021522295 A JP2021522295 A JP 2021522295A JP 2020561004 A JP2020561004 A JP 2020561004A JP 2020561004 A JP2020561004 A JP 2020561004A JP 2021522295 A JP2021522295 A JP 2021522295A
Authority
JP
Japan
Prior art keywords
prion
serpina3
use according
disease
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020561004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522295A5 (enExample
Inventor
ジュゼッペ・レニャメ
シルヴィア・ヴァンニ
パオロ・カルローニ
マルコ・デ・ヴィーヴォ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Fondazione Istituto Italiano di Tecnologia
Original Assignee
Forschungszentrum Juelich GmbH
Fondazione Istituto Italiano di Tecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH, Fondazione Istituto Italiano di Tecnologia filed Critical Forschungszentrum Juelich GmbH
Publication of JP2021522295A publication Critical patent/JP2021522295A/ja
Publication of JP2021522295A5 publication Critical patent/JP2021522295A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020561004A 2018-04-30 2019-04-30 プリオンおよびプリオン様疾患の治療のためのｓｅｒｐｉｎ阻害剤 Withdrawn JP2021522295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18170092.3 2018-04-30
EP18170092.3A EP3563848A1 (en) 2018-04-30 2018-04-30 Serpin inhibitors for the treatment of prion and prion-like diseases
PCT/EP2019/061014 WO2019211265A1 (en) 2018-04-30 2019-04-30 Serpin inhibitors for the treatment of prion and prion-like diseases

Publications (2)

Publication Number Publication Date
JP2021522295A true JP2021522295A (ja) 2021-08-30
JP2021522295A5 JP2021522295A5 (enExample) 2022-05-12

Family

ID=62104124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561004A Withdrawn JP2021522295A (ja) 2018-04-30 2019-04-30 プリオンおよびプリオン様疾患の治療のためのｓｅｒｐｉｎ阻害剤

Country Status (4)

Country Link
US (1) US20210093626A1 (enExample)
EP (2) EP3563848A1 (enExample)
JP (1) JP2021522295A (enExample)
WO (1) WO2019211265A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120392971A (zh) * 2025-04-30 2025-08-01 北京蓬勃力量生物科技有限公司 一种重组蛋白在治疗肌肉萎缩中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ284157B6 (cs) * 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
HRP20000724A2 (en) * 1998-05-05 2001-06-30 Hoffmann La Roche Pyrazole derivatives as p-38 map kinase inhibitors
PL2298743T3 (pl) * 2003-06-26 2013-02-28 Novartis Ag Inhibitory kinaz P38 na bazie 5-członowych heterocykli
EP2099766A1 (en) * 2006-12-20 2009-09-16 Glaxo Group Limited Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands
EP2415471A1 (en) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia

Also Published As

Publication number Publication date
WO2019211265A1 (en) 2019-11-07
US20210093626A1 (en) 2021-04-01
EP3787619A1 (en) 2021-03-10
EP3563848A1 (en) 2019-11-06
EP3787619B1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
Magga et al. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease
Companys-Alemany et al. NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice
JP2021006552A (ja) アルツハイマー病と関連疾患の治療のための併用療法
CA3197716A1 (en) A method of treating depression by immune modulation
CA2829039C (en) Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods thereof
Panegyres et al. Therapies for human prion diseases
Lotz et al. The role of amyloidogenic protein oligomerization in neurodegenerative disease
CA2918340C (en) Rhynchophylline derivatives and their use as epha4 inhibitors for neuroprotection
JP7823101B2 (ja) Ａβ４２オリゴマー形成に関連する疾患の治療のための小分子薬剤、及び関連する方法
Balu et al. A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice
JP7805052B2 (ja) 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法
JP2021522295A (ja) プリオンおよびプリオン様疾患の治療のためのｓｅｒｐｉｎ阻害剤
GB2571978A (en) Uses, compositions and methods
CN112313230A (zh) 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物
US20190262323A1 (en) Compositions and methods for treating neurodegenerative disorders
JP5068164B2 (ja) タウオパシーの治療のための組成物および方法
JP6649396B2 (ja) 新規な１，４−ビス（３−アミノプロピル）ピペラジン誘導体及びその使用
JP2015503598A (ja) 治療的使用
Cho et al. Neuroinflammation-Modulating agent SB1617 enhances LC3-Associated phagocytosis to mitigate Tau pathology
WO2022024072A1 (en) N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
US20130102538A1 (en) Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
EP4534545A1 (en) Novel peptide and use thereof
KR20220139737A (ko) 메나퀴논-7을 유효성분으로 포함하는 퇴행성 신경질환 치료 또는 예방용 조성물
KR20200005314A (ko) 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220428

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230428